During the recent session, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s traded shares were 1.12 million, with the beta value of the company hitting 2.21. At the last check today, the stock’s price was $0.19, reflecting an intraday loss of -3.78% or -$0.01. The 52-week high for the TNXP share is $3.75, that puts it down -1873.68 from that peak though still a striking 10.53% gain since the share price plummeted to a 52-week low of $0.17. The company’s market capitalization is $16.14M, and the average intraday trading volume over the past 10 days was 5.46 million shares, and the average trade volume was 1.93 million shares over the past three months.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information
Tonix Pharmaceuticals Holding Corp (TNXP) registered a -3.78% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.78% in intraday trading to $0.19, hitting a weekly high. The stock’s 5-day price performance is -41.57%, and it has moved by -47.38% in 30 days. Based on these gigs, the overall price performance for the year is -94.71%. The short interest in Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is 0.97 million shares and it means that shorts have 0.76 day(s) to cover.
Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts
Statistics show that Tonix Pharmaceuticals Holding Corp has outperformed its competitors in share price, compared to the industry in which it operates. Tonix Pharmaceuticals Holding Corp (TNXP) shares have gone down -64.23% during the last six months, with a year-to-date growth rate more than the industry average at 56.06% against 9.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 58.50% this quarter and then jump 47.00% in the quarter after that. In the rating firms’ projections, revenue will increase 115.90% compared to the previous financial year.
Revenue for the current quarter is expected to be $7.5 million as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to $7.9 million by the end of Jun 2024.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 79.31%. While earnings are projected to return -102.91% in 2024.
TNXP Dividends
Tonix Pharmaceuticals Holding Corp is due to release its next quarterly earnings between May 06 and May 10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders
Tonix Pharmaceuticals Holding Corp insiders own 0.01% of total outstanding shares while institutional holders control 28.61%, with the float percentage being 28.61%. Vanguard Group Inc is the largest shareholder of the company, while 48 institutions own stock in it. As of Jun 29, 2023, the company held over 0.4 million shares (or 2.24% of all shares), a total value of $0.63 million in shares.
The next largest institutional holding, with 0.21 million shares, is of Renaissance Technologies, LLC’s that is approximately 1.19% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $0.33 million.
Also, the Mutual Funds coming in first place with the largest holdings of Tonix Pharmaceuticals Holding Corp (TNXP) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 0.3 million shares. This amounts to just over 1.67 percent of the company’s overall shares, with a $0.47 million market value. The same data shows that the other fund manager holds slightly less at 0.1 million, or about 0.57% of the stock, which is worth about $0.16 million.
